Skip to content

XOMA Corporation XOMA Investing Cash Flow

Investing Cash Flow at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
-$94.35M-2,028%
Royalty Pharma logo
Royalty PharmaRPRX
-$477.87M-195%
Theravance Biopharma logo
Theravance BiopharmaTBPH
$52.59M+71.7%
Innoviva, Inc. logo
Innoviva, Inc.INVA
$37.01M+207%
Zymeworks logo
ZymeworksZYME
$69.96M+474%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-$49M-141%

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's investing cash flow?
XOMA Corporation (XOMA) reported investing cash flow of $6.55M in Q1 2026.
How has XOMA Corporation's investing cash flow changed year-over-year?
XOMA Corporation's investing cash flow increased by 197.9% year-over-year, from -$6.69M to $6.55M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.